Bausch Health Cos Inc. (NYSE:BHC) Receives Average Recommendation of “Reduce” from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been assigned a consensus rating of “Reduce” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.00.

A number of research firms have commented on BHC. Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Barclays lowered their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, February 25th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Finally, Royal Bank Of Canada reduced their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th.

Institutional Investors Weigh In On Bausch Health Cos

A number of hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd bought a new stake in Bausch Health Cos during the 1st quarter worth $68,000. Jones Financial Companies Lllp grew its position in Bausch Health Cos by 1,548.9% during the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after acquiring an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Bausch Health Cos by 97.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after acquiring an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bausch Health Cos by 3.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after acquiring an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Bausch Health Cos by 11.2% in the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock valued at $5,597,000 after buying an additional 84,892 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $5.42 on Friday. The stock’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $6.15. Bausch Health Cos has a one year low of $4.41 and a one year high of $8.69. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The firm has a market cap of $2.03 billion, a PE ratio of -1.67 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. As a group, research analysts expect that Bausch Health Cos will post 4.08 EPS for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.